Health insurance; electronic prior authorization, report.
Summary
HB2525 revises Virginia’s health insurance prior authorization rules for prescription drugs and expands the state’s electronic prior authorization framework. It requires carrier contracts with participating providers to accept prior authorization requests electronically, telephonically, or by fax; respond within specified timeframes; explain denials; maintain tracking systems; publish formularies and prior authorization forms in one website location; and honor certain prior authorizations across dosage changes, plan changes, and carrier changes. The bill also limits when an approved authorization may be revoked and creates special protections for medication-assisted treatment drugs and certain mental health drugs, including a prohibition on additional prior authorization in some circumstances after an initial approval and continuous use.
Impact
The bill amends Code of Virginia § 38.2-3407.15:2 and updates the 2023 enactment directing the State Corporation Commission’s Bureau of Insurance to convene a work group. It adds a new requirement for carriers, beginning July 1, 2025, to maintain an online electronic prior authorization process integrated with e-prescribing and electronic health record systems, including real-time benefit and out-of-pocket cost information, and it requires providers to ensure their systems can access that process. The measure also narrows the scope of the work group’s charge toward assessing implementation progress and recommending future expansion of electronic prior authorization beyond prescription drugs to surgeries and other medical items and services, with a final report due in 2028. Certain coverages and plans, including Medicare, Medicaid, CHIP, federal employee plans, TRICARE, workers’ compensation, and some dental, optometric, and specified HMO arrangements, remain exempt.
Sentiment
The bill appears to have broad bipartisan support and was advanced unanimously at every recorded stage, including subcommittee, committee, and floor votes in both chambers. The voting history suggests little overt opposition to the measure’s overall goal of reducing administrative burden and improving access to prescription drugs through electronic prior authorization. The absence of recorded dissent indicates a generally favorable sentiment among legislators toward streamlining prior authorization and improving transparency for patients and providers.
Contention
There is little evidence of major controversy in the recorded votes, but the bill does contain policy tradeoffs that could be points of concern. Carriers may view the mandated response deadlines, website publication requirements, and limits on revoking approvals as operationally burdensome, while providers may support the reduced paperwork and continuity protections. The most notable substantive tensions are between insurer utilization management and patient/provider continuity of care, especially for mental health medications, medication-assisted treatment, and prior authorizations that should carry over across plan changes or formulary changes. The work group’s expanded mandate to consider electronic prior authorization for surgeries and other procedures may also raise implementation and technology-readiness concerns for stakeholders.